Date: 2015-09-21
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the Inaugural CRI-CIMT-EATI-AACR Immunotherapy Conference in New York
Company: Nektar Therapeutics (USA - CA)
Product: NKTR-214
Action mechanism: cytokine/proteine/immunotherapy product. NKTR-214 is a CD122-biased immune-stimulatory cytokine, which is designed to stimulate the patient's own immune system to eliminate cancer cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase the proliferation of CD8-positive effector T cells, and these CD8-positive T cells comprise a key component of the tumor infiltrating lymphocytes that provide cell-mediated anti-tumor effects. By biasing activation to the CD122 receptor, NKTR-214 enhances CD8-positive T cells (tumor-killing cells) in the tumor. In preclinical studies, a single dose of NKTR-214 resulted in an approximate 400-fold AUC exposure within the tumor compared with an equivalent dose of aldesleukin, an existing IL-2 therapy. This increase potentially enables, for the first time, an antibody-like dosing regimen for a cytokine. In dosing studies in non-human primates, there was no evidence of low blood pressure or vascular leak syndrome with NKTR-214 at predicted clinical therapeutic doses.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: